TrialJournal of internal medicine2022

Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial.

Marthe Kirkesaether Brun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.